Shanghai, China

Wenming Ren

USPTO Granted Patents = 1 

 

 

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):

Title: Innovator Spotlight: Wenming Ren and His Contributions to Oncology

Introduction: Wenming Ren is a notable inventor based in Shanghai, China. He has made significant strides in the field of medicinal chemistry, particularly focusing on compounds that exhibit potential in cancer treatment. His contributions are underscored by his patented invention, which showcases a promising avenue for therapy in challenging cancer types.

Latest Patents: Wenming Ren holds a patent titled "O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof." This patent pertains to an innovative compound characterized by a structure represented by formula (I). The compound demonstrates remarkable inhibitory activity against both FGFR and RET targets, while maintaining relatively low activity against KDR. In preclinical studies, it has shown substantial inhibition of growth in human lung cancer (NCI-H1581) and gastric cancer cell lines (SNU16), as well as a RET-dependent sensitive cell line (BaF3-CCDC6-Ret) and its mutant. Pharmacokinetic studies indicate that this compound possesses druggability, resulting in notable tumor growth inhibition in long-term efficacy models while ensuring favorable conditions in animal subjects at effective doses.

Career Highlights: Wenming Ren is affiliated with the Shanghai Institute of Materia Medica, which is part of the Chinese Academy of Sciences. His work focuses on developing innovative therapeutic agents that target critical pathways in cancer biology. Through rigorous research and dedication, he has positioned himself as a leader in medicinal chemistry, particularly in relation to oncology.

Collaborations: Throughout his career, Wenming Ren has collaborated with distinguished colleagues such as Youhong Hu and Meiyu Geng. These partnerships have fostered a collaborative research environment, driving innovation in the development of new therapeutic compounds and enhancing the overall impact of their work.

Conclusion: Wenming Ren's contributions to the field of medicinal chemistry, particularly in oncology, are noteworthy. His patented compound, with its dual-target inhibitory activity and positive pharmacokinetic profile, offers exciting possibilities for cancer treatment. As he continues his research at the Shanghai Institute of Materia Medica, the scientific community eagerly anticipates further advancements stemming from his innovative work.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…